BC Innovations | Feb 15, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Cytomegalovirus (CMV) Cell culture studies suggest inhibiting ACSS2 could help treat CMV infection. In two human foreskin fibroblast cell lines infected with human CMV, ACSS2 knockout decreased viral titers compared with normal ACSS2 expression....
BC Innovations | Mar 12, 2015
Distillery Therapeutics

Therapeutics: Acyl-CoA synthetase short-chain family member 2 (ACSS2)

Cancer INDICATION: Cancer Studies in cell culture, mice and patient samples suggest inhibiting ACSS2 could help treat cancer. ACSS2 converts acetate to acetyl-CoA as part of the Krebs cycle, which oxidizes acetate to produce energy....
BC Innovations | Feb 5, 2015
Distillery Therapeutics

Therapeutics: Acyl-CoA synthetase short-chain family member 2 (ACSS2)

Cancer INDICATION: Cancer Mouse and patient studies suggest inhibiting ACSS2 could help treat cancer. In patient breast tumor samples, elevated ACSS2 levels were associated with advanced tumor stage and poor survival. In mouse xenograft models...
BC Innovations | Sep 18, 2014
Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Anemia Acyl-CoA synthetase short-chain family member 2 (ACSS2); endothelial PAS domain protein 1 (EPAS1; HIF2A); erythropoietin (EPO) Mouse studies suggest acetate supplementation could help treat...
Items per page:
1 - 4 of 4